Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Biochem Cell Biol. 2007;39(3):469-77. Epub 2006 Oct 10.

Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions.

Author information

1
School of Anatomy and Human Biology, University of Western Australia, Crawley, Australia.

Abstract

Duchenne muscular dystrophy is a lethal X-linked muscle disease resulting from a defect in the muscle membrane protein dystrophin. The absence of dystrophin leads to muscle membrane fragility, muscle death (necrosis) and eventual replacement of skeletal muscle by fat and fibrous connective tissue. Extensive muscle wasting and respiratory failure results in premature death often by the early 20s. This short review evaluates drug and nutritional interventions designed to reduce the severity of muscular dystrophy, while awaiting the outcome of research into therapies to correct the fundamental gene defect. Combinations of dietary supplementation with amino-acids such as creatine, specific anti-inflammatory drugs and perhaps drugs that target ion channels might have immediate realistic clinical benefits although rigorous research is required to determine optimal combinations of such interventions.

PMID:
17137828
DOI:
10.1016/j.biocel.2006.09.009
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center